Trending NewsTrending NewsTop-Rated StocksTop-RatedNASDAQ:BBIO BridgeBio Pharma (BBIO) Stock Price, News & Analysis $46.58 +0.63 (+1.37%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$46.54 -0.04 (-0.09%) As of 08/8/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About BridgeBio Pharma Stock (NASDAQ:BBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BridgeBio Pharma alerts:Sign Up Key Stats Today's Range$45.40▼$47.2450-Day Range$35.46▼$49.2152-Week Range$21.72▼$49.77Volume2.50 million shsAverage Volume2.96 million shsMarket Capitalization$8.90 billionP/E RatioN/ADividend YieldN/APrice Target$61.35Consensus RatingBuy Company Overview BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California. Read More BridgeBio Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks94th Percentile Overall ScoreBBIO MarketRank™: BridgeBio Pharma scored higher than 94% of companies evaluated by MarketBeat, and ranked 60th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingBridgeBio Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 17 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBridgeBio Pharma has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BridgeBio Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BridgeBio Pharma are expected to grow in the coming year, from ($3.67) to ($2.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BridgeBio Pharma is -11.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BridgeBio Pharma is -11.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.19% of the outstanding shares of BridgeBio Pharma have been sold short.Short Interest Ratio / Days to CoverBridgeBio Pharma has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in BridgeBio Pharma has recently decreased by 10.77%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBridgeBio Pharma does not currently pay a dividend.Dividend GrowthBridgeBio Pharma does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-2.31 Percentage of Shares Shorted10.19% of the outstanding shares of BridgeBio Pharma have been sold short.Short Interest Ratio / Days to CoverBridgeBio Pharma has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in BridgeBio Pharma has recently decreased by 10.77%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment0.45 News SentimentBridgeBio Pharma has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 28 news articles for BridgeBio Pharma this week, compared to 10 articles on an average week.Search Interest23 people have searched for BBIO on MarketBeat in the last 30 days. This is an increase of 92% compared to the previous 30 days.MarketBeat Follows14 people have added BridgeBio Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, BridgeBio Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $369,921,586.00 in company stock.Percentage Held by Insiders18.20% of the stock of BridgeBio Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.85% of the stock of BridgeBio Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BridgeBio Pharma's insider trading history. Receive BBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address BBIO Stock News HeadlinesBridgeBio Pharma, Inc. (BBIO) Q2 2025 Earnings Call Transcript2 hours ago | seekingalpha.comQ3 Earnings Forecast for BBIO Issued By Leerink Partnrs4 hours ago | americanbankingnews.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)Oppenheimer Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock PriceAugust 8 at 2:35 AM | americanbankingnews.comBridgeBio Pharma Sees Unusually High Options Volume (NASDAQ:BBIO)August 8 at 2:34 AM | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Shares Gap Down on Disappointing EarningsAugust 8 at 2:45 AM | americanbankingnews.comBridgeBio Reports Second Quarter 2025 Financial Results and Business UpdatesAugust 5, 2025 | globenewswire.comBridgeBio Pharma Q2 2025 Earnings PreviewAugust 5, 2025 | msn.comSee More Headlines BBIO Stock Analysis - Frequently Asked Questions How have BBIO shares performed this year? BridgeBio Pharma's stock was trading at $27.44 on January 1st, 2025. Since then, BBIO shares have increased by 69.8% and is now trading at $46.58. How were BridgeBio Pharma's earnings last quarter? BridgeBio Pharma, Inc. (NASDAQ:BBIO) announced its quarterly earnings results on Tuesday, August, 5th. The company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by $0.12. BridgeBio Pharma's quarterly revenue was up 4999.9% compared to the same quarter last year. Read the conference call transcript. When did BridgeBio Pharma IPO? BridgeBio Pharma (BBIO) raised $225 million in an initial public offering on Thursday, June 27th 2019. The company issued 15,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR served as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers. Who are BridgeBio Pharma's major shareholders? BridgeBio Pharma's top institutional shareholders include Geode Capital Management LLC (1.93%), Emerald Advisers LLC (0.54%), Emerald Mutual Fund Advisers Trust (0.34%) and Portman Square Capital LLP. Insiders that own company stock include Global Investors Lp Viking, Genetic Disorder LP Kkr, Neil Kumar, Frank Mccormick, Maricel Apuli, Brian C Stephenson, Andrea Ellis, Hannah Valantine and Randal W Scott. View institutional ownership trends. How do I buy shares of BridgeBio Pharma? Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BridgeBio Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that BridgeBio Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), CrowdStrike (CRWD) and ServiceNow (NOW). Company Calendar Last Earnings8/05/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - GENERIC DRG Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BBIO CIK1743881 Webbridgebio.com Phone(650) 391-9740FaxN/AEmployees400Year FoundedN/APrice Target and Rating Average Price Target for BridgeBio Pharma$61.35 High Price Target$95.00 Low Price Target$46.00 Potential Upside/Downside+31.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($4.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$535.76 million Net Margins-329.25% Pretax Margin-331.52% Return on EquityN/A Return on Assets-85.69% Debt Debt-to-Equity RatioN/A Current Ratio5.19 Quick Ratio4.54 Sales & Book Value Annual Sales$221.90 million Price / Sales40.13 Cash FlowN/A Price / Cash FlowN/A Book Value($9.30) per share Price / Book-5.01Miscellaneous Outstanding Shares191,170,000Free Float155,323,000Market Cap$8.90 billion OptionableOptionable Beta1.23 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:BBIO) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.